<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2790-8305</journal-id>
<journal-title><![CDATA[Revista Científica CMDLT]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Cien CMDLT]]></abbrev-journal-title>
<issn>2790-8305</issn>
<publisher>
<publisher-name><![CDATA[Centro Médico Docente La Trinidad]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2790-83052022000100201</article-id>
<article-id pub-id-type="doi">10.55361/cmdlt.v16i1.158</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Valor diagnóstico y pronóstico de la procalcitonina en pacientes con sepsis hospitalizados en el Centro Médico Docente La Trinidad]]></article-title>
<article-title xml:lang="en"><![CDATA[Diagnostic and prognostic value of procalcitonin in patients with sepsis hospitalized at Centro Medico Docente La Trinidad]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Medina]]></surname>
<given-names><![CDATA[Valentina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Morante]]></surname>
<given-names><![CDATA[María Mercedes]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ferrer]]></surname>
<given-names><![CDATA[José Luis]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Centro Médico Docente La Trinidad  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Venezuela</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2022</year>
</pub-date>
<volume>16</volume>
<numero>1</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://ve.scielo.org/scielo.php?script=sci_arttext&amp;pid=S2790-83052022000100201&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://ve.scielo.org/scielo.php?script=sci_abstract&amp;pid=S2790-83052022000100201&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://ve.scielo.org/scielo.php?script=sci_pdf&amp;pid=S2790-83052022000100201&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen Sepsis se define como un síndrome de anormalidades fisiológicas, bioquímicas y patológicas en respuesta a un agente infeccioso, el cual representa mortalidad y riesgo de complicaciones y discapacidades. Para su diagnóstico, se emplea la escala de SOFA, la cual presenta resultados de laboratorio y características clínicas. Considerando la gran cantidad de elementos que incluye, y la necesidad de abordar de manera expedita a estos pacientes por su mortalidad y repercusión sobre calidad de vida, al igual que su impacto sobre la salud pública, se plantea el uso de la Procalcitonina (PCT) como marcador diagnóstico, por su rápida elevación en infecciones bacterianas y descenso oportuno en fase de resolución. Por la frecuencia hospitalaria de deterioro y complicaciones severas como consecuencia de sepsis en el CMDLT, se busca evaluar el rendimiento diagnóstico y pronóstico de la PCT como biomarcador de sepsis en pacientes con patología infecciosa a través de un estudio observacional, analítico, transversal, retrospectivo en los años 2019 y 2020. Se revisaron 243 historias clínicas de pacientes con patología infecciosa, se aplicó la escala de SOFA y se eligieron 73 pacientes y a 33 se les midió PCT al ingreso. El 24,2% pacientes presento PCT negativa y 75,8% pacientes PCT positiva. El foco más común de la sepsis fue el entero-biliar. La puntuación de la escala de SOFA guardó relación con un peor pronóstico de la sepsis. La positivización de la PCT se correlacionó con un peor desenlace de la enfermedad, como ingreso a Unidad de Cuidados Intensivos (UCI) o muerte.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Sepsis is defined as a syndrome with physiological, biochemical and pathologic abnormalities in response to an infectious agent; which represents great mortality, along with risk of complications and disabilities. For its diagnosis, the SOFA score, from Sequential Organ Assessment Failure, is applied, which consists of laboratory and clinical findings. Considering the quantity of items it includes, and the expedite necessity to diagnose these patients in awe of its mortality and repercussion on life quality, along its impact on the healthcare system, the use of Procalcitonin (PCT) as a diagnostic marker has been proposed, because of its quick elevation on bacterial infections andits decrease amongst resolution. Due to the frequency of deterioration and severe complications as consequence of sepsis in Centro Médico Docente La Trinidad (CMDLT), we aim to establish the performance of PCT as a biomarker for diagnosis and prognosis of hospitalized patients with sepsis through an analytical observational retrospective study between the years 2019 and 2020. The medical records from 243 patients with infectious disease were examined, then, SOFA Scale was applied, electing 73 patients, to whom 33 of them were solicited Procalcitonin levels. We found that 24.2% of patients had negative PCT levels, while 75.8% were positive. The most common infection site was abdominal. The SOFA score showed correlation to a worse prognosis in these patients. It was determined that PCT positivization was related to a worse outcome of the disease, like admission to the Intensive Care Unit (ICU) or death.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[sepsis]]></kwd>
<kwd lng="es"><![CDATA[escala de SOFA]]></kwd>
<kwd lng="es"><![CDATA[Procalcitonina]]></kwd>
<kwd lng="es"><![CDATA[biomarcador]]></kwd>
<kwd lng="es"><![CDATA[diagnóstico]]></kwd>
<kwd lng="es"><![CDATA[pronóstico]]></kwd>
<kwd lng="en"><![CDATA[sepsis]]></kwd>
<kwd lng="en"><![CDATA[SOFA score]]></kwd>
<kwd lng="en"><![CDATA[Procalcitonin]]></kwd>
<kwd lng="en"><![CDATA[biomarker]]></kwd>
<kwd lng="en"><![CDATA[diagnosis]]></kwd>
<kwd lng="en"><![CDATA[prognosis]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Singer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Deutschman]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[Seymour]]></surname>
<given-names><![CDATA[CW]]></given-names>
</name>
<name>
<surname><![CDATA[Shankar-Hari]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Annane]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2016</year>
<volume>315</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>801-10</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fleischmann]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Scherag]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Adhikari]]></surname>
<given-names><![CDATA[NK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Assessment of Global Incident and Mortality of Hospital-Treated Sepsis. Current Estiment and Limitations]]></article-title>
<source><![CDATA[Am J Respir Crit Care Med]]></source>
<year>2016</year>
<volume>193</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>259-72</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vijayan]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Vanimaya]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ravindran]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Procalcitonin: a promising diagnostic marker for sepsis and antibiotic therapy]]></article-title>
<source><![CDATA[J Intensive Care]]></source>
<year>2017</year>
<volume>5</volume>
<page-range>51</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schuetz]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Birkhahn]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Sherwin]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
<name>
<surname><![CDATA[Singer]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Serial Procalcitonin Predicts Mortality in Severe Sepsis Patients: Results From the Multicenter Procalcitonin Monitoring SEpsis (MOSES) Study]]></article-title>
<source><![CDATA[Crit Care Med]]></source>
<year>2017</year>
<volume>45</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>781-9</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sun Ju]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Sumg Oh]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Yong Won]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Jun Hyeok]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Kyoung-Chul]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Procalcitonin as a diagnostic marker for sepsis/ septic shock in the emergency department; a study based on Sepsis-3 definition]]></article-title>
<source><![CDATA[Am J Emerg Med]]></source>
<year>2019</year>
<volume>37</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>272-6</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Manzur-Jattin]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Ramos-Villegas]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Quintana-Pájaro]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Corrales-Santander]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Muñoz-Báez]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[PCT como marcador pronostico y diagnostico en pacientes con injuria miocárdica]]></article-title>
<source><![CDATA[Archivos de Medicina]]></source>
<year>2018</year>
<volume>14</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>1-3</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maruna]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Nedelníková]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Gürlich]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Physiology and genetics of procalcitonin]]></article-title>
<source><![CDATA[Physiol Res]]></source>
<year>2000</year>
<volume>49</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>57-61</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hatzistilianou]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnostic and Prognostic Role of Procalcitonin in Infections]]></article-title>
<source><![CDATA[TheScientificWorldJournal]]></source>
<year>2010</year>
<volume>10</volume>
<page-range>1941-6</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Meisner]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pathobiochemestry and clinical use of procalcitonin]]></article-title>
<source><![CDATA[Clinica Chimica Acta]]></source>
<year>2002</year>
<volume>323</volume>
<page-range>17-29</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Meisner]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Update of Procalcitonin Measurements]]></article-title>
<source><![CDATA[Ann Lab Med]]></source>
<year>2014</year>
<volume>34</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>263-73</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Paudel]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Dogra]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Montgomery-Yates]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Coz Yataco]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Procalcitonin: A promising tool or just another overhyped test?]]></article-title>
<source><![CDATA[Int J Med Sci]]></source>
<year>2020</year>
<volume>17</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>332-7</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schuetz]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Albrich]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
<name>
<surname><![CDATA[Mueller]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future]]></article-title>
<source><![CDATA[BMC Med]]></source>
<year>2011</year>
<volume>9</volume>
<page-range>107</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Becker]]></surname>
<given-names><![CDATA[K.L.]]></given-names>
</name>
<name>
<surname><![CDATA[Nylén]]></surname>
<given-names><![CDATA[E.S.]]></given-names>
</name>
<name>
<surname><![CDATA[White]]></surname>
<given-names><![CDATA[J.C.]]></given-names>
</name>
<name>
<surname><![CDATA[Müller]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Snider Jr]]></surname>
<given-names><![CDATA[R.H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Procalcitonin and de Calcitonin Gene Family of Peptides in Inflammation, Infection and Sepsis: A Journey from Calcitonin Back to its Precursors]]></article-title>
<source><![CDATA[J. Clin. Endocrinol. Metab]]></source>
<year>2004</year>
<volume>89</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1512-25</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kip]]></surname>
<given-names><![CDATA[MMA]]></given-names>
</name>
<name>
<surname><![CDATA[van Oers]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Shajiei]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Beishuizen]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Berghuis]]></surname>
<given-names><![CDATA[AMS]]></given-names>
</name>
<name>
<surname><![CDATA[Girbes]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[de Jong]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[de Lange]]></surname>
<given-names><![CDATA[DW]]></given-names>
</name>
<name>
<surname><![CDATA[Nijsten]]></surname>
<given-names><![CDATA[MWN]]></given-names>
</name>
<name>
<surname><![CDATA[IJzerman]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Koffijberg]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Kusters]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost- effectiveness of procalcitonin testing to guide antibiotic treatment duration in critically ill patients: results from a randomised controlled multicentre trial in the Netherlands]]></article-title>
<source><![CDATA[Crit Care]]></source>
<year>2018</year>
<volume>22</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>293</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Salinas]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[López-Garrigós]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Flores]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Uris]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Leiva- Salinas]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Procalcitonin in the Emergency Departament: A potencial expensive over-request that can be modulated to intitucional protocols]]></article-title>
<source><![CDATA[Am J Emerg Med]]></source>
<year>2018</year>
<volume>36</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>158-60</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yunus]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Fasih]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The use of procalcitonin in the determination of severity of sepsis, patient outcomes and infection characteristics]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2018</year>
<volume>13</volume>
<numero>11</numero>
<issue>11</issue>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Becker]]></surname>
<given-names><![CDATA[KL]]></given-names>
</name>
<name>
<surname><![CDATA[Snider]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Nylen]]></surname>
<given-names><![CDATA[ES]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and a therapeutic target]]></article-title>
<source><![CDATA[Br J Pharmacol]]></source>
<year>2010</year>
<volume>159</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>253-364</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hecker]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Reichert]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Reub]]></surname>
<given-names><![CDATA[C.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Schmoch]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Riedel]]></surname>
<given-names><![CDATA[J.E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intra-abdominal sepsis: new definition and current clinical standards]]></article-title>
<source><![CDATA[Langenbeck&#8217;s Arch Surg]]></source>
<year>2019</year>
<volume>404</volume>
<page-range>257-71</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gorordo-Delson]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez-Nieto]]></surname>
<given-names><![CDATA[OR]]></given-names>
</name>
<name>
<surname><![CDATA[Porras-Escorcia]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Altamirano-Arcos]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sepsis abdominal: fisiopatología, diagnóstico y tratamiento]]></article-title>
<source><![CDATA[Rev Mex Cirug Apart Diges]]></source>
<year>2015</year>
<volume>4</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>110-7</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
